FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to pharmaceutics. First invention represents a tablet containing: (a) an extrudate, including: (i) a polymer matrix which is a water-soluble copolymer of vinylpyrrolidone and vinyl acetate; (ii) a dispersant; and (iii) a compound of formula I or a pharmaceutically acceptable salt thereof:
Formula I
where Ra is independently -H or -F, wherein dispersing agent and compound of Formula I are dispersed in said polymer matrix; and (b) a disintegrating system comprising powdered sodium chloride and sodium croscarmellose. Second invention is a composition suitable for pressing into a tablet, and a third invention is a tablet with tensile strength of 1.75 MPa, obtained by pressing said composition.
EFFECT: technology of preparing tablets for cgrp-active compounds is disclosed.
19 cl, 3 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYMER COMPOSITIONS OF CETP INHIBITORS | 2007 |
|
RU2457841C2 |
| PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
| PRO-MEDICATION COMPOSITION FOR STRUGGLE AGAINST HEPAPATITIS C VIRUS | 2006 |
|
RU2435592C2 |
| COMPOSITIONS OF SOLID DOSAGE FORMS OF OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2759837C2 |
| ANTIRETROVIRAL COMBINATION | 2008 |
|
RU2531089C2 |
| THE METHOD OF OBTAINING A PHARMACEUTICAL COMPOSITION WITH TACROLIMUS (VARIANTS) AND A PHARMACEUTICAL COMPOSITION OBTAINED BY THESE METHODS | 2022 |
|
RU2792098C1 |
| COMPOSITIONS OF SOLID DOSAGE FORMS OF AN OREXIN RECEPTOR ANTAGONIST | 2013 |
|
RU2699358C2 |
| ANTI-RETROVIRAL COMBINATION | 2014 |
|
RU2675831C2 |
| PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
| COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION | 2008 |
|
RU2500398C2 |
